Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ovid Therapeutics ( (OVID) ) has issued an announcement.
On October 2, 2025, Ovid Therapeutics entered into a Securities Purchase Agreement to issue and sell Series B convertible preferred stock and warrants in a private placement, potentially raising up to $175.1 million. The proceeds will be used for research and development, corporate expenses, and working capital. Additionally, Ovid announced positive results from a Phase 1 study of OV329, a GABA-aminotransferase inhibitor for drug-resistant epilepsies, showing strong inhibitory activity and a favorable safety profile, with plans to advance to Phase 2a trials.
The most recent analyst rating on (OVID) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.
Spark’s Take on OVID Stock
According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.
Ovid Therapeutics’ stock score is primarily influenced by its financial performance challenges, including revenue volatility and ongoing losses. The technical analysis indicates strong upward momentum, but the high beta suggests volatility. Valuation remains a concern with a negative P/E ratio and no dividend yield. Positive corporate events, such as the Nasdaq transfer and financial agreements, provide some stability and potential for future growth.
To see Spark’s full report on OVID stock, click here.
More about Ovid Therapeutics
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions with significant unmet needs.
Average Trading Volume: 2,126,674
Technical Sentiment Signal: Buy
Current Market Cap: $116.6M
For an in-depth examination of OVID stock, go to TipRanks’ Overview page.